Evaluation of treatment response for immune checkpoint inhibitors in non-small cell lung cancer patients using [18F]F-AraG PET/CT

Not Applicable

Recruiting

• Conditions: on-small cell lung cancer; lung cancer; D002289

• Registration Number: JPRN-jRCTs051220109
• Lead Sponsor: akamoto Yuji

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2022-10-26
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

1) Confirmed non-small cell lung cancer by pathology.
2) Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 or 2.
3) Patients without history of immune checkpoint inhibitors approved in Japan, but clinically applicable and planned to be prescribed.
4) Patients who performed FDG-PET/CT

Exclusion Criteria

1) Pregnant, possibly pregnant, or breastfeeding women.
2) Very poor physical condition.
3) Outstandingly difficult in communication.

Study & Design

• Study Type: Interventional
• Study Design: Not specified